Method for preventing and/or treating insulin resistance
View Patent ↗Described is the use of Eubacterium hallii et rel. and/or Alcaligenes faecalis et rel., as well as pharmaceutical, food, or feed compositions comprising these bacteria as a medicament, in particular, for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as metabolic syndrome, dyslipidemia and type 2 diabetes mellitus, as well as insulin resistance in endocrine diseases (e.g., obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes. Also described is a method for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as dyslipidemia and type 2 diabetes mellitus as well as insulin resistance in endocrine diseases (e.g., obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes) in a subject in need thereof, the method comprising the step of increasing the level of Eubacterium hallii et rel. and/or Alcaligenes faecalis et rel. in the small intestine.
1. A method of treating insulin resistance and/or an insulin resistance-related complication in a human subject diagnosed with insulin resistance and/or an insulin resistance-related complication, the method comprising:
administering to the human subject an effective amount of Eubacterium hallii et relatives so as to treat insulin resistance and/or an insulin resistance-related complication in the human subject.
2. The method according to claim 1 , wherein the insulin resistance-related complication is selected from the group consisting of metabolic syndrome, dyslipidemia, insulin-resistance in endocrine disease, and type 2 diabetes mellitus.
3. The method according to claim 1 , wherein the Eubacterium hallii et relatives is administered as a pharmaceutical, food, or feed composition comprising the E. hallii et relatives.
4. The method according to claim 3 , wherein the insulin resistance-related complication is selected from the group consisting of metabolic syndrome, dyslipidemia, insulin-resistance in endocrine disease, and type 2 diabetes mellitus.
5. A method for treating insulin resistance and/or an insulin resistance-related complication in a human subject in need thereof, the method comprising:
increasing, by an effective amount, the level of Eubacterium hallii et relatives in the human subject's small intestine.
6. The method according to claim 5 , wherein the level of Eubacterium hallii et relatives in the human subject's small intestine is increased by a method selected from the group consisting of administering an effective amount of Eubacterium hallii et relatives to the subject and administering an effective amount of a compound capable of increasing the level of Eubacterium hallii et relatives in the small intestine.
7. The method according to claim 5 , wherein the insulin resistance-related conditions are selected from the group consisting of metabolic syndrome, dyslipidemia, insulin resistance in endocrine disease, and type 2 diabetes mellitus.
8. The method according to claim 6 , wherein the insulin resistance-related conditions are selected from the group consisting of metabolic syndrome, dyslipidemia, insulin resistance in endocrine disease, and type 2 diabetes mellitus.
9. The method according to claim 3 , wherein the Eubacterium hallii et relatives is administered in lyophilized form.
10. The method according to claim 9 , wherein the Eubacterium hallii et relatives are formulated with a cryoprotectant.
11. The method according to claim 3 , wherein the Eubacterium hallii et relatives are administered in a solid dosage form.
12. The method according to claim 11 , wherein the solid dosage form is selected from the group consisting of a capsule, a tablet, and a powder.
13. The method according to claim 3 , wherein the Eubacterium hallii et relatives is administered in a liquid dosage form.
14. The method according to claim 13 , wherein the liquid dosage form is selected from the group consisting of an elixir, syrup, and suspension.
15. The method according to claim 2 , wherein the insulin resistance-related condition comprises insulin resistance in endocrine disease in an obese human subject having a disease selected from the group consisting of type 1 diabetes mellitus, Cushing's disease, and lipodystrophy syndrome.
16. The method according to claim 4 , wherein the insulin resistance-related condition comprises insulin resistance in endocrine disease in an obese human subject having a disease selected from the group consisting of type 1 diabetes mellitus, Cushing's disease, and lipodystrophy syndrome.
17. The method according to claim 7 , wherein the insulin resistance-related condition comprises insulin resistance in endocrine disease in an obese human subject having a disease selected from the group consisting of type 1 diabetes mellitus, Cushing's disease, and lipodystrophy syndrome.
18. The method according to claim 8 , wherein the insulin resistance-related condition comprises insulin resistance in endocrine disease in an obese human subject having a disease selected from the group consisting of type 1 diabetes mellitus, Cushing's disease, and lipodystrophy syndrome.
19. The method according to claim 1 , wherein the Eubacterium hallii is Eubacterium hallii strain L2-7 (DSM 17630).
20. A method of altering fasting plasma glucose levels in a human subject suffering from insulin resistance and/or insulin resistance-related complication, the method comprising:
administering to the human subject an effective amount of Eubacterium hallii et relatives so as to alter the fasting plasma glucose levels in the subject.
21. A method of altering fasting insulin levels in a human subject suffering from insulin resistance and/or insulin resistance-related complication, the method comprising:
administering to the human subject an effective amount of Eubacterium hallii et relatives so as alter the fasting insulin levels in the subject.
22. A method of altering postprandial glucose level in a human subject suffering from insulin resistance and/or insulin resistance-related complications, the method comprising:
administering to the human subject an effective amount Eubacterium hallii et relatives so as to alter the postprandial glucose level in the subject.
23. The method according to claim 1 , wherein the treatment of insulin resistance and/or an insulin resistance-related complication in the human subject is determined by fasting plasma glucose and insulin levels or hyperinsulinemic clamps or by utilizing an oral glucose tolerance test.
24. The method according to claim 5 , wherein the treatment of insulin resistance and/or an insulin resistance-related complication in the human subject is determined by fasting plasma glucose and insulin levels or hyperinsulinemic clamps or by utilizing an oral glucose tolerance test.